Pathway-based polygenic risk scores for schizophrenia and associations with clinical and neuroimaging phenotypes in UK Biobank - Barbu, Miruna C.; Thng, Gladi; Adams, Mark J.; Marwick, Katie; Grant, Seth; McIntosh, Andrew M.; Lawrie, Stephen M.; Whalley, Heather C. (medRxiv, 2022)
Background Schizophrenia is a heritable psychiatric disorder with a polygenic architecture. Genome-wide association studies (GWAS) have reported an increasing number of risk-associated variants and polygenic risk scores (PRS) now explain 17% of the variance in the disorder. There exists substantial heterogeneity in the effect of these variants and aggregating them based on biologically relevant functions may provide mechanistic insight into the disorder.Methods Using the largest schizophrenia GWAS to date, we calculated PRS based on 5 pathways previously found to contribute to the pathophysiology of schizophrenia: the postsynaptic density, postsynaptic membrane, dendritic spine, axon, and histone H3-K4 methylation pathways. We associated each PRS, along with respective whole-genome PRS (excluding single nucleotide polymorphisms in each pathway), with neuroimaging (N>29,000; cortical, subcortical, and white matter microstructure) and clinical (N>119,000; psychotic-like experiences including conspiracies, communications, voices, visions, and distress) variables in healthy subjects in UK Biobank.Findings A number of clinical and neuroimaging variables were significantly associated with the axon pathway (psychotic-like communications: β=0.0916, pFDR=0.04, parahippocampal gyrus volume: β=0.0156, pFDR=0.03, FA thalamic radiations: β=-0.014, pFDR=0.036, FA posterior thalamic radiations: β=-0.016, pFDR=0.048), postsynaptic density pathway (distress due to psychotic-like experiences: β=0.0588, pFDR=0.02, global surface area: β=-0.012, pFDR=0.034, and cingulate lobe surface area: β=- 0.014, pFDR=0.04), and histone pathway (entorhinal surface area: β=-0.016, pFDR=0.035). In the associations above, whole-genome PRS were significantly associated with psychotic-like communications (β=0.2218, pFDR=1.34×10−7), distress (β=0.1943, pFDR=7.28×10−16), and FA thalamic radiations (β=-0.0143, pFDR=0.036). Permutation analysis carried out for these associations revealed that they were not due to chance.Discussion Our results indicate that genetic variation in 3 pathways relevant to schizophrenia (axon, postsynaptic density, histone) may confer risk for the disorder through effects on a number of neuroimaging variables that have previously been implicated in schizophrenia. As neuroimaging associations were stronger for pathway PRS than whole-genome PRS, findings here highlight that selection of biologically relevant variants may address the heterogeneity of the disorder by providing further mechanistic insight into schizophrenia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in whole, or in part, by the Wellcome Trust [216767/Z/19/Z]. This analysis uses linked data from UKB applications 4844 and 16124. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. MCB is supported by a Guarantors of Brain Non-clinical Post-Doctoral Fellowship and British Medical Association Margaret Temple Grant. HCW is supported by the Royal College of Physicians of Edinburgh (Sim Fellowship). MJA is supported by MRC Mental Health Data Pathfinder Award (MC_PC_17209). KM is supported by the Chief Scientist Office for Scotland and NHS Education for Scotland (PCL/17/01). This study is supported by a Wellcome Trust Strategic Award "Stratifying Resilience and Depression Longitudinally" (STRADL) (Reference 104036/Z/14/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the research ethics committee (REC reference 11/NW/0382), and this study has been approved by the UK Biobank Access Committee (Project No. 4844 and 16124).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.